Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod

Abby Wills, Guang Fan, Edward Kim, Craig Y. Okada, Kevin P. White, R. Samuel Hopkins

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

A 55-year-old man with relapsing-remitting multiple sclerosis on fingolimod presented to the dermatology clinic with skin lesions on the left temple and cheek. Histopathology showed a diffuse infiltrate of enlarged, atypical lymphocytes throughout the dermis with an overlying grenz zone and a subpopulation of scattered smaller lymphocytes and plasma cells. Epstein-Barr virusencoded RNA in situ hybridization stain was positive. Based on the morphologic and immunophenotypic findings, a diagnosis of EBV-positive diffuse large Bcell lymphoma was made. This case aims to raise awareness for the dermatologist that patients on fingolimod may be at increased risk of lymphoproliferative disorders.

Original languageEnglish (US)
Article numberA364
JournalDermatology Online Journal
Volume25
Issue number9
DOIs
StatePublished - 2019

Keywords

  • DLBCL
  • Diffuse large Bcell lymphoma
  • EBV-positive DLBCL
  • Fingolimod
  • Multiple sclerosis
  • Primary cutaneous B-cell lymphoma
  • Primary cutaneous Epstein-Barr virus-positive lymphoma
  • Primary cutaneous diffuse large B-cell lymphoma
  • Primary cutaneous lymphoma

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod'. Together they form a unique fingerprint.

Cite this